338404-52-7
基本信息
6-(4-氯苯基)咪唑并[2,1-B]噻唑-5-甲醛 O-(3,4-二氯苄基)肟
物理化学性质
| 密度 | 1.48±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | DMSO: 28 mg/mL, soluble |
| 溶解度 | DMSO：28 mg/mL，可溶 |
| 酸度系数(pKa) | 4.05±0.40(Predicted) |
| 形态 | solid |
| 颜色 | Light yellow to yellow |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 26-36 |
| WGK Germany | 3 |
| WGK Germany | 3 |
常见问题列表
CAR, PXR
CITCO (1-50 μM; 48 hours) results in a dose-dependent inhibition of viable cell count and proliferation in both T98G and U87MG glioma and BTSCs.
CITCO (2.5, 5 μM; 48 hours) induces cell cycle arrest differentially in different BTSCs in culture, but not in normal astrocytes.
CITCO (2.5-10 μM; 48 hours) induces apoptosis in BTSCs in culture in dose dependently, but not in normal astrocytes.
CITCO (0-25 μM; 48 hours) causes the T98G and U87MG glioma and BTSCs expressing very low levels of CAR protein that increased significantly.
Cell Proliferation Assay
| Cell Line: | T98G, U87MG, DB29 and DB33 human glioma cells, astrocytes |
| Concentration: | 1, 2.5, 5, 10, 25, 50 μM |
| Incubation Time: | 48 hours |
| Result: | Resulted in a dose-dependent inhibition of viable cell count and proliferation. |
Cell Cycle Analysis
| Cell Line: | The T98G, U87MG, DB29 and DB33 glioma cells |
| Concentration: | 2.5, 5 μM |
| Incubation Time: | 48 hours |
| Result: | Induced cell cycle arrest differentially in different BTSCs in culture. |
Apoptosis Analysis
| Cell Line: | The T98G, U87MG, DB29 and DB33 glioma cells |
| Concentration: | 2.5, 5 or 10 μM |
| Incubation Time: | 48 hours |
| Result: | Increased the levels of Annexin V-positive apoptotic cells in dose dependently. |
Western Blot Analysis
| Cell Line: | T98G, U87MG, DB29 and DB33 glioma cells |
| Concentration: | 0 to 25 μM |
| Incubation Time: | 48 hours |
| Result: | The T98G, U87MG glioma and BTSCs expressed very low levels of CAR protein that increased significantly. |
CITCO (intraperitoneal; on days 22, 24, 26, 30 and 36) with 25 μg results a significant decrease in tumour growth, which further decreases to an undetectable level after treatment with 100 μg CITCO .
| Animal Model: | Six- to eight-week-old male athymic nude mice |
| Dosage: | 25 or 100 μg |
| Administration: | Intraperitoneal; on days 22, 24, 26, 30 and 36 |
| Result: | Decreased tumour growth. |